与人工智能聊天,对抗抗生素耐药性:机遇与挑战

IF 3.6 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Current Research in Biotechnology Pub Date : 2024-01-01 DOI:10.1016/j.crbiot.2024.100197
Mohammad Abavisani , Alireza Khoshrou , Sobhan Karbas Foroushan , Amirhossein Sahebkar
{"title":"与人工智能聊天,对抗抗生素耐药性:机遇与挑战","authors":"Mohammad Abavisani ,&nbsp;Alireza Khoshrou ,&nbsp;Sobhan Karbas Foroushan ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.crbiot.2024.100197","DOIUrl":null,"url":null,"abstract":"<div><p>Antibiotic resistance (ABR) is a dire global health crisis, undermining the efficacy of antibiotics and ranking among the top ten public health threats according to the World Health Organization. Despite multifaceted efforts to tackle ABR, complex challenges persist across scientific, economic, behavioral, ethical, and legal dimensions. Artificial intelligence (AI), which encompasses machine capabilities for human-like tasks, offers a wide range of applications in healthcare. Chatbots, a subtype of AI, emerge as a powerful avenue for natural language interaction with users. In healthcare, chatbots have demonstrated value in symptom assessment, mental health support, medication adherence, and patient engagement. In this context, our article will comprehensively examine the opportunities and challenges presented by chatbots in bacterial disease management and ABR mitigation. We will delve into not only the technical considerations but also the ethical, legal, and social complexities accompanying their integration into healthcare. The current consideration will be valuable for healthcare professionals, policymakers, and researchers as they navigate the dynamic intersection of chatbots and the pressing issue of antibiotic resistance.</p></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590262824000236/pdfft?md5=510a3f6da3dcf5ee6fd73f2a753f14e1&pid=1-s2.0-S2590262824000236-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Chatting with artificial intelligence to combat antibiotic resistance: Opportunities and challenges\",\"authors\":\"Mohammad Abavisani ,&nbsp;Alireza Khoshrou ,&nbsp;Sobhan Karbas Foroushan ,&nbsp;Amirhossein Sahebkar\",\"doi\":\"10.1016/j.crbiot.2024.100197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Antibiotic resistance (ABR) is a dire global health crisis, undermining the efficacy of antibiotics and ranking among the top ten public health threats according to the World Health Organization. Despite multifaceted efforts to tackle ABR, complex challenges persist across scientific, economic, behavioral, ethical, and legal dimensions. Artificial intelligence (AI), which encompasses machine capabilities for human-like tasks, offers a wide range of applications in healthcare. Chatbots, a subtype of AI, emerge as a powerful avenue for natural language interaction with users. In healthcare, chatbots have demonstrated value in symptom assessment, mental health support, medication adherence, and patient engagement. In this context, our article will comprehensively examine the opportunities and challenges presented by chatbots in bacterial disease management and ABR mitigation. We will delve into not only the technical considerations but also the ethical, legal, and social complexities accompanying their integration into healthcare. The current consideration will be valuable for healthcare professionals, policymakers, and researchers as they navigate the dynamic intersection of chatbots and the pressing issue of antibiotic resistance.</p></div>\",\"PeriodicalId\":52676,\"journal\":{\"name\":\"Current Research in Biotechnology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590262824000236/pdfft?md5=510a3f6da3dcf5ee6fd73f2a753f14e1&pid=1-s2.0-S2590262824000236-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Research in Biotechnology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590262824000236\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590262824000236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

抗生素耐药性(ABR)是一个严峻的全球健康危机,它破坏了抗生素的疗效,被世界卫生组织列为十大公共卫生威胁之一。尽管为解决抗生素耐药性问题做出了多方面的努力,但在科学、经济、行为、伦理和法律等方面仍然存在复杂的挑战。人工智能(AI)包括机器执行类似人类任务的能力,在医疗保健领域有着广泛的应用。聊天机器人是人工智能的一个子类型,是与用户进行自然语言交互的强大途径。在医疗保健领域,聊天机器人在症状评估、心理健康支持、用药依从性和患者参与等方面都体现出了价值。在此背景下,我们的文章将全面探讨聊天机器人在细菌性疾病管理和 ABR 缓解方面带来的机遇和挑战。我们不仅将深入探讨技术方面的考虑因素,还将探讨将聊天机器人融入医疗保健的伦理、法律和社会复杂性。在医疗保健专业人员、政策制定者和研究人员探索聊天机器人与抗生素耐药性这一紧迫问题的动态交叉点时,当前的考虑将对他们很有价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Chatting with artificial intelligence to combat antibiotic resistance: Opportunities and challenges

Antibiotic resistance (ABR) is a dire global health crisis, undermining the efficacy of antibiotics and ranking among the top ten public health threats according to the World Health Organization. Despite multifaceted efforts to tackle ABR, complex challenges persist across scientific, economic, behavioral, ethical, and legal dimensions. Artificial intelligence (AI), which encompasses machine capabilities for human-like tasks, offers a wide range of applications in healthcare. Chatbots, a subtype of AI, emerge as a powerful avenue for natural language interaction with users. In healthcare, chatbots have demonstrated value in symptom assessment, mental health support, medication adherence, and patient engagement. In this context, our article will comprehensively examine the opportunities and challenges presented by chatbots in bacterial disease management and ABR mitigation. We will delve into not only the technical considerations but also the ethical, legal, and social complexities accompanying their integration into healthcare. The current consideration will be valuable for healthcare professionals, policymakers, and researchers as they navigate the dynamic intersection of chatbots and the pressing issue of antibiotic resistance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Research in Biotechnology
Current Research in Biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.70
自引率
3.60%
发文量
50
审稿时长
38 days
期刊介绍: Current Research in Biotechnology (CRBIOT) is a new primary research, gold open access journal from Elsevier. CRBIOT publishes original papers, reviews, and short communications (including viewpoints and perspectives) resulting from research in biotechnology and biotech-associated disciplines. Current Research in Biotechnology is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Biotechnology (2018 CiteScore 8.450) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.
期刊最新文献
Engineering yeast lipids for production of designer biodiesel Table of Contents Dolastatins and their analogues present a compelling landscape of potential natural and synthetic anticancer drug candidates Drug Discovery, Diagnostic, and therapeutic trends on Mpox: A patent landscape Life cycle and environmental impact assessment of vegetation-activated sludge process (V-ASP) for decentralized wastewater treatment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1